[Chain News] PANews, June 18th - Eyenovia, a Nasdaq-listed company focused on digital ophthalmic medical technology development, announced the completion of a $50 million PIPE financing, which will be used to purchase Hyperliquid’s native token HYPE and plans to become one of its major global validation nodes. The total fundraising cap for this transaction is expected to be $150 million, and the company will also change its name to “Hyperion DeFi,” with the stock code changing to “HYPD.” The new Chief Investment Officer, Hyunsu Jung, will be responsible for executing the encryption treasury strategy. Eyenovia will also continue to advance its FDA registration plan for ophthalmic devices, aiming to complete it by September 2025.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Eyenovia, a Nasdaq company, completed a $50 million financing to purchase HYPE and become a validating Node.
[Chain News] PANews, June 18th - Eyenovia, a Nasdaq-listed company focused on digital ophthalmic medical technology development, announced the completion of a $50 million PIPE financing, which will be used to purchase Hyperliquid’s native token HYPE and plans to become one of its major global validation nodes. The total fundraising cap for this transaction is expected to be $150 million, and the company will also change its name to “Hyperion DeFi,” with the stock code changing to “HYPD.” The new Chief Investment Officer, Hyunsu Jung, will be responsible for executing the encryption treasury strategy. Eyenovia will also continue to advance its FDA registration plan for ophthalmic devices, aiming to complete it by September 2025.